ROCO
4171
Market cap32mUSD
Nov 13, Last price
21.85TWD
Name
GeneReach Biotechnology Corp
Chart & Performance
P/E
—
P/S
4.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
19.65%
Revenues
206m
-8.41%
Net income
-119m
L-28.59%
CFO
-23m
L-39.95%
Dividend
Jul 28, 20231.5 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers automatic nucleic acid extraction systems, prep homogenization system, and mini centrifuge equipment; and reagents and consumables, comprising human IVD assays, iiPCR specific reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and research reagents and consumables. The company also provides polymerase chain reaction training programs, molecular diagnostic technical solutions, laboratory installation services, OEM/ODM contract manufacturing services, and research collaboration services. It serves aquaculture, agriculture, food, and human health industries, as well as companion animals and livestock. GeneReach Biotechnology Corp. was founded in 2004 and is headquartered in Taichung, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||